Erasca, Inc. Common Stock
ERAS
$16.76
-6.26%
Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. As a niche player in the biotechnology industry, it distinguishes itself through a modality-agnostic pipeline targeting key signaling nodes, RAS directly, and escape routes. The current investor narrative centers on the company's rapid clinical progress, particularly its pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, which have driven a dramatic stock surge in 2026 amid heightened interest in RAS-targeted therapies.…
ERAS
Erasca, Inc. Common Stock
$16.76
Investment Opinion: Should I buy ERAS Today?
Rating: Buy. Thesis: Erasca offers asymmetric upside from its pan-RAS pipeline, supported by strong analyst consensus and recent momentum, but investors must accept binary risk and potential dilution. The average analyst target of $21.90 implies 14.2% upside, and the high target of $30.00 suggests 56.5% potential.
Supporting Evidence: (1) Consensus Buy rating from 10 analysts with a mean score of 1.6. (2) Price-to-book of 3.24 is below the industry average of 4-5x for pre-revenue biotechs, suggesting relative value. (3) Revenue growth is not applicable, but pipeline advancement is accelerating with two clinical-stage programs. (4) The company has a strong current ratio of 10.0 and low debt-to-equity of 0.14, providing financial flexibility. (5) The stock has surged 1,186% YoY, indicating strong momentum.
Risks & Conditions: The biggest risks are clinical trial failure and cash burn. If ERAS-0015 or ERAS-4001 fail, the stock could fall to $12 (low target) or below. This Buy rating would downgrade to Hold if the stock approaches the high target of $30 without new catalysts, or to Sell if cash runway shortens to less than 12 months. Valuation verdict: ERAS is fairly valued relative to its pipeline stage, with a PB of 3.24 near the middle of its historical range (0.87-12.51).
Sign up to view all
ERAS 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by strong price momentum and analyst support. However, the lack of revenue and high cash burn temper conviction. The base case of steady pipeline progress is most likely (50% probability), with the stock trading in the $18-$24 range. Key catalysts include clinical data readouts and potential partnerships. The stance would upgrade to high confidence if the company reports positive Phase 2 data, and downgrade to neutral if cash runway falls below 12 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Erasca, Inc. Common Stock's 12-month outlook, with a consensus price target around $24.30 and implied upside of +45.0% versus the current price.
Average Target
$24.30
0 analysts
Implied Upside
+45.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$20 - $33
Analyst target range
Erasca is covered by 10 analysts, with a consensus recommendation of 'Buy' (mean score 1.6 on a 1-5 scale, where 1 is Strong Buy). The average target price is $21.90, implying 14.2% upside from the current price of $19.17. The distribution leans bullish, with no sell ratings and several recent upgrades, including B of A Securities moving from Underperform to Neutral in June 2026. The target range spans from $12.00 (low) to $30.00 (high). The high target of $30.00 assumes successful clinical data and potential regulatory acceleration, while the low target of $12.00 reflects risks of trial failures or dilution. The spread of $18.00 between low and high indicates high uncertainty, typical for a clinical-stage biotech. Recent ratings actions show a pattern of upgrades and reiterations, with firms like Mizuho, Stifel, and JP Morgan maintaining positive stances, suggesting growing confidence in the pipeline. However, the wide target range underscores that outcomes remain binary.
Bulls vs Bears: ERAS Investment Factors
Erasca presents a high-risk, high-reward profile typical of clinical-stage biotechs. The bull case is anchored by a 1,186% YoY stock surge, consensus Buy rating with 14% upside, and a strong balance sheet with minimal debt. However, the bear case highlights zero revenue, deepening losses of $183.4 million in Q1 2026, high cash burn, and binary trial outcomes. The most critical tension is whether the pan-RAS pipeline will deliver clinical success before cash runs out, forcing dilutive financing. Currently, the bullish momentum and analyst support outweigh bearish financials, but the risk of trial failure remains the single most important factor that could reverse the thesis.
Bullish
- Explosive 1,186% YoY Price Surge: ERAS has surged 1,186.6% over the past year, dramatically outperforming the S&P 500's 18.35% gain. This reflects strong investor conviction in the company's pan-RAS pipeline, particularly ERAS-0015 and ERAS-4001, which have driven a massive re-rating.
- Consensus Buy Rating with 14% Upside: 10 analysts rate ERAS a Buy (mean 1.6 on 1-5 scale) with an average target of $21.90, implying 14.2% upside from $19.17. The high target of $30.00 suggests potential for 56.5% gains if clinical data exceeds expectations.
- Strong Liquidity with Minimal Debt: Current ratio of 10.0 and debt-to-equity of 0.14 indicate a solid balance sheet. The company raised $244.7 million from stock issuance in Q1 2026, providing ample runway to fund clinical trials without immediate financing pressure.
- Favorable Industry Tailwinds for RAS Targeting: Erasca's focus on RAS/MAPK pathway cancers positions it in a high-demand niche. Recent successes in RAS-targeted therapies have heightened investor interest, and the company's modality-agnostic approach offers multiple shots on goal.
Bearish
- No Revenue and Deepening Losses: Erasca has zero revenue and reported a net loss of $183.4 million in Q1 2026, up from $30.9 million a year earlier. The negative trailing PE of -8.45 and forward PE of -34.67 indicate the market expects losses to persist and widen.
- High Cash Burn and Dilution Risk: Free cash flow was negative $27.4 million in Q1 2026, and cash stood at only $47.3 million. The company raised $244.7 million via stock issuance in the quarter, diluting existing shareholders. Further equity raises are likely, pressuring the stock.
- Binary Clinical Trial Outcomes: As a clinical-stage biotech, ERAS's valuation hinges on trial results. The wide analyst target range ($12-$30) reflects high uncertainty. A single trial failure could erase gains, as seen in the 59.46% max drawdown from the 52-week high.
- Valuation Stretched on Book Value: Price-to-book of 3.24 is above the industry median for pre-revenue biotechs (typically 2-3x). While below its historical peak of 12.51, the current PB implies the market is pricing in significant pipeline success that may not materialize.
ERAS Technical Analysis
Erasca is in a powerful sustained uptrend, with the stock surging 1,186.6% over the past year. The current price of $19.17 sits at 78.9% of its 52-week range ($1.33 to $24.28), indicating strong momentum but not yet at overbought extremes near the high. This positioning suggests the uptrend remains intact, though the stock is approaching resistance levels that could test buying conviction. Short-term momentum is accelerating sharply, with a 1-month gain of 37.1% and a 3-month gain of 0.8% (the latter reflecting a pullback from April highs). The divergence between the explosive 1-month rally and the flat 3-month performance signals a recent recovery from a mid-April selloff, potentially marking a resumption of the long-term uptrend. The stock's beta of 0.665 indicates it is less volatile than the market, which is unusual given its massive price swings, suggesting the moves are driven by company-specific catalysts rather than broad market forces. Key resistance is at the 52-week high of $24.28, a breakout above which would signal a continuation of the uptrend and likely attract further buying. Support lies at the 52-week low of $1.33, though the stock is far above that level; more immediate support may be around $10, the post-April consolidation zone. A breakdown below $10 would negate the recent recovery and suggest a return to range-bound trading.
Beta
0.65
0.65x market volatility
Max Drawdown
-59.5%
Largest decline past year
52-Week Range
$1-$24
Price range past year
Annual Return
+967.5%
Cumulative gain past year
| Period | ERAS Return | S&P 500 |
|---|---|---|
| 1m | -7.7% | +2.0% |
| 3m | +27.2% | +1.0% |
| 6m | +7.9% | +11.8% |
| 1y | +967.5% | +18.1% |
| ytd | +366.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ERAS Fundamental Analysis
Erasca has no revenue, as it is a pre-commercialization biotechnology company focused on clinical development. The most recent quarter (Q1 2026) reported zero revenue, consistent with all prior quarters, and the company's growth trajectory is measured by pipeline advancement rather than top-line sales. The investment case hinges on clinical trial results and regulatory milestones, not revenue growth. The company is deeply unprofitable, with a net loss of $183.4 million in Q1 2026, compared to $30.9 million in Q1 2025, reflecting a significant increase in spending. Gross margin is negative due to cost of revenue exceeding zero revenue, and operating expenses surged to $37.9 million in Q1 2026 from $35.6 million a year earlier, driven by higher R&D costs ($27.3 million vs. $25.9 million). The widening losses are typical for a clinical-stage biotech investing heavily in late-stage trials. Erasca's balance sheet shows a current ratio of 10.0, indicating strong liquidity, and a debt-to-equity ratio of 0.14, suggesting minimal leverage. However, free cash flow was negative $27.4 million in Q1 2026, and the company has relied on equity financing, raising $244.7 million from stock issuance in the quarter. With cash of $47.3 million at quarter-end, the company may need additional capital to fund operations beyond the near term, though the recent stock price surge provides favorable conditions for further equity raises.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-91364000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ERAS Overvalued?
Since Erasca has negative net income and EBITDA, we use the price-to-sales (PS) ratio, but the PS ratio is zero because the company has no revenue. Instead, we evaluate valuation using the price-to-book (PB) ratio, which is 3.24, and the negative earnings-based multiples. The trailing PE is -8.45 and forward PE is -34.67, indicating the market expects losses to persist and widen. The large gap between trailing and forward PE reflects anticipated higher net losses as the company scales clinical programs. Compared to the biotechnology industry average PB ratio (typically around 4-5x for pre-revenue biotechs), Erasca's PB of 3.24 is at a discount, suggesting the market is not pricing in significant asset value. However, this discount may be justified by the company's lack of approved products and high cash burn rate. Historically, Erasca's PB ratio has ranged from 0.87 to 12.51 over the past five years. The current PB of 3.24 is near the middle of this range, below the peak of 12.51 in mid-2021 when the stock was newly listed and investor enthusiasm was high. This suggests the current valuation is not excessively stretched relative to its own history, but the stock has already priced in substantial pipeline optimism.
PE
-8.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Erasca's primary financial risk is its cash burn rate. With zero revenue and a net loss of $183.4 million in Q1 2026, the company's cash of $47.3 million provides limited runway. The negative free cash flow of $27.4 million in Q1 and reliance on equity financing ($244.7 million raised in Q1) create dilution risk. The debt-to-equity ratio of 0.14 is low, but the company's ability to fund operations without further capital raises is uncertain. Operating expenses are rising, with R&D costs of $27.3 million in Q1 2026 versus $25.9 million a year earlier, indicating increasing spending on clinical trials.
Market & Competitive Risks: Erasca's valuation is highly sensitive to clinical trial outcomes, as evidenced by the 59.46% max drawdown from its 52-week high. The stock's beta of 0.665 suggests lower market correlation, but company-specific risks dominate. The biotechnology sector is competitive, with many companies targeting RAS pathways. Regulatory headwinds or delays in FDA approvals could derail timelines. The wide analyst target range ($12-$30) underscores uncertainty. Recent upgrades (e.g., B of A Securities from Underperform to Neutral) show improving sentiment, but the stock remains vulnerable to negative trial data.
Worst-Case Scenario: The worst-case scenario involves a clinical trial failure for ERAS-0015 or ERAS-4001, leading to a loss of investor confidence and a sharp sell-off. The stock could fall to its 52-week low of $1.33, representing a 93.1% decline from the current price of $19.17. This scenario would likely trigger analyst downgrades and force the company to raise capital at depressed prices, further diluting shareholders. The historical max drawdown of 59.46% from the 52-week high of $24.28 to the April 2026 low of $9.11 provides a more moderate downside reference, but a complete pipeline failure could be more severe.
FAQ
The primary risk is clinical trial failure, which could cause the stock to fall to the 52-week low of $1.33 (93% downside). Financial risks include cash burn: free cash flow was negative $27.4 million in Q1 2026, and cash of $47.3 million may not last beyond 2027 without additional financing. Dilution risk is high, as the company raised $244.7 million from stock issuance in Q1 2026. Competitive risks include other companies developing RAS-targeted therapies, which could erode Erasca's market opportunity. Regulatory risks include delays or safety holds on clinical programs.
The 12-month forecast is based on three scenarios. The base case (50% probability) sees the stock trading between $18 and $24, near the analyst average of $21.90, assuming steady clinical progress. The bull case (25% probability) targets $24.28 to $30.00, driven by positive clinical data and regulatory catalysts. The bear case (25% probability) targets $9.11 to $12.00, reflecting a clinical setback. The most likely scenario is the base case, with the stock consolidating recent gains. Key assumptions include successful Phase 2 data for ERAS-0015 and no major financing issues.
Erasca's valuation is difficult to assess due to zero revenue and negative earnings. The price-to-book ratio of 3.24 is below the biotechnology industry average of 4-5x for pre-revenue companies, suggesting it may be undervalued relative to peers. However, the trailing PE of -8.45 and forward PE of -34.67 indicate the market expects losses to widen. Historically, the PB has ranged from 0.87 to 12.51, and the current level is near the middle, implying it is not excessively stretched. The valuation implies the market is pricing in a high probability of clinical success, which may or may not materialize.
ERAS is a high-risk, high-reward stock suitable for investors who can tolerate binary outcomes. The consensus Buy rating from 10 analysts and average target of $21.90 (14.2% upside) suggest near-term potential. However, the company has zero revenue, a net loss of $183.4 million in Q1 2026, and a cash burn rate that may require dilutive financing. The stock has already surged 1,186% in the past year, pricing in significant pipeline optimism. For risk-tolerant investors with a long-term view, it could be a good buy if clinical trials succeed. For conservative investors, the risk of a 93% decline to the 52-week low of $1.33 is too high.
ERAS is best suited for long-term investment (3-5 years) given its clinical-stage nature, as drug development timelines are lengthy. The stock's beta of 0.665 suggests lower market correlation, but its volatility is driven by company-specific events, making it risky for short-term trading. The stock has no dividend, and earnings visibility is low. A minimum holding period of 3 years is recommended to allow for clinical trial readouts and potential regulatory approvals. Short-term traders may profit from momentum, but the risk of sharp drawdowns (59.46% max drawdown) is high.